Pap Cytology and Hybrid Capture 2 HPV DNA Testing in 234 Patients with Cervical Squamous Cell Carcinoma.
Zaibo Li, Marshall R Austin, Ming Guo, Chengquan Zhao. Magee Women's Hospital of UPMC, Pittsburgh, PA; The University of Texas MD Anderson Cancer Center, Houston
Background: Cervical cancer screening with Pap cytology and HPV DNA testing is highly sensitive in predicting cervical precancerous lesions (CIN2/3). However, patients with CIN2/3 or even carcinoma can be missed during the screening. To evaluate the factors that resulted in the screening failure, we compared history of Pap cytology and HPV DNA testing results in patients with cervical squamous cell carcinoma (SQC).
Design: We conducted a computer-based search for a 5-year period and collected the results of surgical pathology, ThinPrep Pap, and Hybrid Capture 2 (HC2) HPV DNA testing from patients with cervical SQC. HPV DNA testing using PCR was performed on the surgical specimens from the cases with negative HC2 test.
Results: 234 patients with SQC were identified, including 35 cases of microinvasive SQC. The average age was 48 years (22 to 84 years). The clinical or Pap findings leading to the diagnostic biopsies are detailed in table 1.
|No. of Patients (% of subcategory)||%|
|cervical lesions||44 (77.2%)|
|Pap Test||Case No.||%|
|At least one prior abnormal Pap||22||64.7%|
|At least one prior normal Pap||15||44.1%|
|Both prior normal and abnormal Pap||3||8.8%|